Cookies on this website
We use cookies to ensure that we give you the best experience on our website. If you click 'Continue' we'll assume that you are happy to receive all cookies and you won't see this message again. Click 'Find out more' for information on how to change your cookie settings.

The £13m drug discovery partnership between Oxford University, Oxford Sciences Innovation and Evotec supported 12 new projects in first year of operation.

Thomas Hanke © John Cairns
Thomas Hanke, Expert-in-Residence at Evotec

LAB282, the £13m drug discovery partnership between Oxford University, Oxford Sciences Innovation and Evotec, is celebrating its first year of operation after successfully accelerating 12 drug discovery and development projects at the University.

In total, the partnership has provided 14 awards, both small and large scale.

In its fourth and latest round of awards, LAB282 backed the following Oxford projects:

  • Validation of novel targets for myelofibrosis, a severe bone marrow disorder.
  • Development of glucosidase II interface inhibitors; towards a novel class of broad-spectrum antivirals.
  • Discovery of potent inhibitors to DarG antitoxins as a first-in-class anti-microbial concept.
  • Advancing the development of evasins, a novel class of chemokine-trap to treat inflammatory disorders.

Find out more (Oxford University Innovation website)

Similar stories

New blood-based test is the first ever to simultaneously identify if a patient has cancer and if it has spread

A publication by University of Oxford researchers describes a new minimally invasive and inexpensive blood test that can identify cancer in patients with non-specific symptoms. The early success of this technology makes it the first blood-based test that not only detects cancer in this population but can simultaneously identify if a cancer has spread.

Alan Davidson Foundation supports ground-breaking Motor Neurone Disease research

A £210,000 donation from the Alan Davidson Foundation (ADF) has been made to the Nuffield Department of Clinical Neurosciences (NDCN) to advance the University’s world leading research into Motor Neurone Disease (MND). The funding will support a project manager for three years to deliver an innovative research project using the genetic causes of MND to develop approaches to early diagnosis and eventually, prevention of all forms of MND.

New Oxford-GSK Institute to harness advanced technology and unravel mechanisms of disease

GlaxoSmithKline plc and the University of Oxford today announced a major five-year collaboration to establish the Oxford-GSK Institute of Molecular and Computational Medicine.

Jenner Institute named Covid Innovation Heroes

The team at the University of Oxford’s Jenner Institute has been celebrated for their global pandemic work by The Oxford Trust’s Covid Innovation Heroes Award­ 2021.

Oxford joins consortium to advance quantum drug discovery with £6.8M grant from Innovate UK

Oxford University today joins a consortium led by the digital quantum computing company, SEEQC, to build and deliver a full-stack quantum computer for pharmaceutical drug development for Merck KGaA.

AIMday in Women's Health - registration for academics now open

Are you an academic interested in finding out how your knowledge can be used to solve industry challenges? Would you like to widen your network? Meet potential collaborators / future employees? Gain insights into relevant funding schemes? If you answer YES to any of the above, now is the time to register for the AIMday in Women's Health.